Treatment of a Patient With Metastatic Gastrointestinal Stromal Tumor
Release Date: February 5, 2009
Expiration Date: February 5, 2010
The management of gastrointestinal stromal tumor (GIST) was markedly changed several years ago by scientific and clinical evidence supporting the integration of kinase-targeted agents into the treatment armamentarium. The management of GIST continues to evolve, with new indications for and clinical trial data on kinase-targeted and other biologic agents. The utilization of molecular assessments to identify patients at high risk of recurrence and to personalize their treatment regimen is becoming an integral part of the management of patients with both resectable and advanced disease. The need for standards in patient selection is underscored by the recent approval of kinase-targeted therapy for patients with resectable KIT+ disease.
The purpose of this activity is to update physicians on current standards regarding devising treatment strategies including kinase-targeted agents based on gross and molecular disease characteristics in patients with KIT+ GIST.
This educational activity is intended for medical oncologists involved in the care of patients with GIST. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.
Upon completion of this educational activity, you should be able to:
Successful completion is determined by a score of 65% or greater.